Sponsored

Invion (ASX: IVX) sees promising research outcomes with PhotosoftTM technology in September quarter - Kalkine Media

November 02, 2022 11:23 AM AEDT | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Invion has made further significant progress in developing the PhotosoftTM technology in the September quarter.
  • In a recent in vitro study, Invion's research partner Peter Mac demonstrated the effectiveness of INV043 against anal cancers.
  • Invion achieved successful results from in vitro studies of PhotosoftTM on Zika and SARS-CoV-2 – delta and omicron variants.

The September quarter of 2022 was a busy period for Invion Limited (ASX: IVX), which reported significant results from its research & development (R&D) activities. The company's major focus remained on advancing the development of its PhotosoftTM technology to treat different types of cancer and infectious diseases.  

The company is undertaking its R&D activities in collaboration with international institutes including the Peter MacCallum Cancer Centre and the Hudson Institute of Medical Research.  

INV043 is effective against anal cancer

INV043 is Invion's lead API for the development of next generation of PDT cancer treatments.

The company’s research partner Peter Mac demonstrated the effectiveness of INV043 against anal cancers in a recent in vitro study. The compound was found to be effective against six squamous cell carcinoma (SCC) cell lines representing the full range of anal cancers.

The results of this study are in line with the positive outcomes achieved by the Hudson Institute on other types of cancers, including triple-negative breast cancer.

Invion's partners are commencing further work on INV043, which is expected to pave the way for human clinical trials. The company anticipates starting at least one of these trials in the first half of CY2023.

PhotosoftTM shows antiviral activity against Zika virus

The quarter saw the release of the first test results using PhotosoftTM on viruses. In in vitro studies conducted by Viroclinics-DDL and Virology Research Services Ltd (VRS), selected PhotosoftTM compounds were found to be effective against the Zika virus.

The study also found these compounds boasting a higher Therapeutic Index than the control Monensin.

Monensin is an antibiotic found to be effective against Zika in in vitro laboratory tests. However, due to its in vivo toxicity, Monensin cannot be used in humans.

Image source: Company update

PhotosoftTM displays antiviral activity against COVID-19

In another set of a study conducted by Viroclinics and VRS, nine out of the ten PhotosoftTM compounds exhibited antiviral activity against the Delta and Omicron BA.1 variants of SARS-CoV-2.

The control used in this study was Remdesivir, a broad-spectrum antiviral medication that has been approved for emergency use in different nations to treat COVID-19.

Five of the tested compounds demonstrated no cytotoxicity, whereas the other five exhibited light-dependent cytotoxicity.

Image source: Company update

Image source: Company update

Financial update

Invion ended the quarter with a cash balance of AU$7.8 million and no debt. The company has a funding agreement with RMW Cho Group.

The company says that it is well-founded to pursue its near-and medium-term development agenda.

Invion shares traded at AU$0.010 with an upsurge of 5% on 02 November 2022.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.